The goal of cancer treatment is to destroy cancer cells, whether through surgery, radiation, drug therapies, or a combination of these. During the course of these treatments, however, healthy cells can also be damaged or destroyed, leading to unpleasant side effects such as electrolyte imbalance, dehydration, weight loss, fatigue, infection, lack of appetite, mouth sores, skin irritations, anemia, and depression. These side effects can frighten and even terrify patients if they have not been educated on what to expect; without proper guidance, these side effects can also lead to emergency department visits and affect treatment adherence and completion.
Each patient with cancer responds differently to treatment, and in the past few years, researchers and providers have discovered better ways to predict, reduce, and even prevent certain side effects, leading, in some cases, to more tolerable treatments and better adherence. Controlling side effects and managing comorbid conditions and risks should be part of every patient’s cancer care program. Clinical, physical, functional, cognitive, and psychosocial assessments, along with education and self-care, are also cornerstones to better care and can be improved when providers and care teams take the following steps:
- Devote more time to patients and their families before treatment selection
- Improve patient education and teaching via conversations between the patient and a provider, care coach, or navigator to explain the risks and benefits of each treatment option
- Complete a thorough medical history and physical examination, and use functional or comorbid tools (eg, Eastern Cooperative Oncology Group performance status, Charlson Comorbidity Index)
- Strengthen patient–doctor communications regarding life-altering side effects.
In 2012, the Healthcare Cost and Utilization Project examined adult cancer hospitalizations using data collected in 2009 from its National Inpatient Sample. The review showed that approximately 4.7 million hospitalizations of adult patients were cancer-related; in 1.2 million (25%) of these hospitalizations, cancer was the principal diagnosis.1 This came at a cost of $20.1 billion in inpatient hospital costs. Patients who incurred the highest daily costs were patients with prostate ($4600), breast ($4100), and thyroid ($3500) cancers. Furthermore, the most common cancer hospitalizations among men were for prostate cancer, secondary malignancies or metastatic cancer, and lung cancer; hospitalizations related to kidney cancer in adult men increased 40% from 2000 to 2009.1 The most common cancer hospitalizations among women were for secondary malignancies as well as for breast and lung cancers. Bronchus, lung, and colon cancers, as well as secondary malignancies, accounted for more than one-third of the total cost of hospital stays for cancer.
In a separate report, investigators with the Healthcare Cost and Utilization Project assessed hospital readmissions in 2009 for cancer surgery in teaching versus nonteaching hospitals in New York. Thirty-day readmissions were assessed from 21,945 admissions for cancer surgery, and the overall readmission rate was 9.3%, with 11.2% of readmissions occurring in nonteaching hospitals, and 8.6% occurring in teaching hospitals.2 Factors that increased the risk for 30-day readmission for a preventable cause among patients with cancer were male sex, undergoing surgery at a nonteaching hospital, African American race, and certain comorbidities.
Little changed in the years that followed. A review of the University HealthSystem Consortium database from 2010 to 2013 by Brown and colleagues demonstrated that Medicare-estimated readmission costs were $17 billion annually, and investigators showed that more than 50% of patients who were discharged after surgery died or were rehospitalized <1 year after discharge.3 The same review found that patients with cancer receiving medical services were readmitted more than patients with cancer receiving surgical services, and noted that National Cancer Institute–designated comprehensive cancer centers had a higher readmission rate than nondesignated cancer centers.
Overall, almost one-third of patients were readmitted to hospitals ≤7 days after discharge; 33% of these readmissions were the result of potentially preventable side effects (eg, nausea, vomiting, dehydration, and postoperative pain).
A study published in October 2014 showed that unplanned hospitalization rates among patients with gastrointestinal cancers are higher than unplanned hospitalizations related to some other cancers, but, most importantly, they are also potentially preventable.4 The study used the Texas Cancer Registry and Medicare claims data for in-hospital admissions from 30,199 patients with gastrointestinal cancer aged ≥66 years. The rate of unplanned hospitalizations was 58.1%, and 55.9% of these hospitalizations occurred within the first year of cancer diagnosis. Moreover, the top reasons for unplanned hospitalizations—fluid and electrolyte disorders, intestinal obstruction, pneumonia, congestive heart failure, chronic obstructive pulmonary disease, and bronchiectasis—were considered potentially preventable, and lead author Joanna-Grace M. Manzano, MD, noted that these comorbidities “may help identify areas of focus for improvement or intervention.” Further analysis revealed that patients with esophageal, gastric, pancreatic, and rectal cancers, as well as patients with regional and distant diseases, were at higher risk for unplanned hospitalizations.
Another prospective study that examined drug-related problems and their correlation with unplanned hospitalizations focused on 2 oncology units with patients diagnosed with solid tumors or lymphoma.5 Results were described as predictable; the incidence of unplanned hospitalizations associated with drug-related problems was 12.4%, approximately half of which were potentially preventable events. The study revealed that the majority of the admissions related to drug-related problems were adverse drug reactions that were moderately severe (N = 155; 94.5%), or probably/definitely preventable (N = 86; 52.4%). It is also important to note that febrile neutropenia was the most common adverse drug reaction, and drug combinations, including antihypertensives and long-term corticosteroids, increased the risk of potential drug–drug interactions.
The key points in most studies were that many of the unplanned hospitalizations that were reported were potentially preventable and were related to patients’ high comorbidity scores. This means that oncologists do not have a clear picture of their patients—or their patients’ expectations—before or while making decisions about the most appropriate cancer treatment. Completing full clinical histories and examinations, as well as cognitive, functional, and psychosocial assessments should not be overlooked or taken for granted. Too often, pretesting and full clinical assessments of patients’ histories and care expectations are overlooked or not revisited once treatment is initiated.
Treating physicians (ie, oncologists, primary care physicians, and other specialists) should recognize that elderly patients who have gastrointestinal cancer are vulnerable to unplanned hospitalizations. Knowing that elderly patients with gastrointestinal cancer are prone to more frequent unplanned hospitalizations, healthcare providers should promote efforts to improve the coordination of care among everyone involved in caring for them. Patients would likely benefit from continued, close follow-up with their oncologists, oncology care managers, or even their primary care physicians during treatment and for years to come. All of this research and information affirms that the burden of readmissions and unplanned hospitalizations caused by side effects and poor symptom management falls on the shoulders of the patients, their families, and ancillary care systems, when it should be the responsibility of the treating physicians and their clinical teams.
Improving side-effect management for patients is a goal for which every oncology clinic and practice should strive. Proactive side-effect education and emotional support for patients and their families, as well as frequent, comprehensive follow-ups and monitoring before, during, and after treatment are essential. These steps can go a long way in keeping patients’ side effects under control and decreasing unplanned hospitalizations. In addition, the use of clinical assessment tools to better understand the patient’s comorbid history, physical health, cognitive function, mental and emotional health, as well as care expectations should be a key part of every oncology practice. Readmissions and unplanned hospitalizations play a role in decreasing a patient’s survival, and oncology care teams must improve side-effect management to prevent this.
- Price RA, Stranges E, Elixhauser A. Cancer hospitalizations for adults, 2009. www.hcup-us.ahrq.gov/reports/statbriefs/sb125.pdf. Published February 2012. Accessed June 8, 2015.
- Kuznar W. Causes of hospital readmissions of patients with cancer. Am Health Drug Benefits. 2013;6:22-23.
- Brown EG, Burgess D, Li C, et al. Hospital readmissions: necessary evil or preventable target for quality improvement. Ann Surg. 2014;260:583-591.
- Manzano JG, Luo R, Elting LS, et al. Patterns and predictors of unplanned hospitalization in a population-based cohort of elderly patients with GI cancer. J Clin Oncol. 2014;32:3527-3533.
- Chan A, Soh D, Ko Y, et al. Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients. Support Care Cancer. 2014;22:1875-1881.